NASDAQ:TNDM Tandem Diabetes Care (TNDM) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free TNDM Stock Alerts $44.72 +8.16 (+22.32%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$42.46▼$47.0050-Day Range$26.58▼$37.0552-Week Range$13.82▼$47.00Volume5.99 million shsAverage Volume1.77 million shsMarket Capitalization$2.89 billionP/E RatioN/ADividend YieldN/APrice Target$40.82 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Tandem Diabetes Care alerts: Email Address Tandem Diabetes Care MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.64 Rating ScoreUpside/Downside2.8% Downside$43.45 Price TargetShort InterestBearish14.31% of Shares Sold ShortDividend StrengthN/ASustainability-0.64Upright™ Environmental ScoreNews Sentiment1.13Based on 24 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.62) to ($1.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.18 out of 5 starsMedical Sector1963rd out of 5,430 stocksSurgical & Medical Instruments Industry259th out of 570 stocks 2.3 Analyst's Opinion Consensus RatingTandem Diabetes Care has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 8 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageTandem Diabetes Care has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted14.31% of the outstanding shares of Tandem Diabetes Care have been sold short.Short Interest Ratio / Days to CoverTandem Diabetes Care has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Tandem Diabetes Care has recently decreased by 0.75%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldTandem Diabetes Care does not currently pay a dividend.Dividend GrowthTandem Diabetes Care does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreTandem Diabetes Care has received a 80.42% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Insulin pumps" product. See details.Environmental SustainabilityThe Environmental Impact score for Tandem Diabetes Care is -0.64. Previous Next 3.4 News and Social Media Coverage News SentimentTandem Diabetes Care has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Tandem Diabetes Care this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for TNDM on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.MarketBeat Follows9 people have added Tandem Diabetes Care to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tandem Diabetes Care insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.20% of the stock of Tandem Diabetes Care is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Tandem Diabetes Care are expected to grow in the coming year, from ($1.62) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tandem Diabetes Care is -13.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tandem Diabetes Care is -13.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTandem Diabetes Care has a P/B Ratio of 9.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Awesomely, LLCAutomatic Income (from home)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. Just click here now to watch my presentation for free. About Tandem Diabetes Care Stock (NASDAQ:TNDM)Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.Read More TNDM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TNDM Stock News HeadlinesMay 3, 2024 | fool.comWhy Tandem Diabetes Stock Just Jumped 22%May 3, 2024 | finance.yahoo.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2024 Earnings Call TranscriptMay 3, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.May 3, 2024 | marketwatch.comTandem Diabetes Care Shares Rise 17% on Raised 2024 Sales OutlookMay 3, 2024 | finance.yahoo.comTandem Diabetes Care Inc (TNDM) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ...May 3, 2024 | finance.yahoo.comQ1 2024 Tandem Diabetes Care Inc Earnings CallMay 2, 2024 | investorplace.comTNDM Stock Earnings: Tandem Diabetes Care Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | businesswire.comTandem Diabetes Care Announces First Quarter 2024 Financial Results and Updates Full Year 2024 Financial GuidanceMay 3, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.May 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM) and Eli Lilly & Co (LLY)May 1, 2024 | americanbankingnews.comTandem Diabetes Care (NASDAQ:TNDM) Stock Rating Upgraded by Wells Fargo & CompanyApril 30, 2024 | msn.comWells Fargo Upgrades Tandem Diabetes Care (TNDM)April 29, 2024 | finance.yahoo.comAre Investors Undervaluing Tandem Diabetes Care, Inc. (NASDAQ:TNDM) By 31%?April 27, 2024 | americanbankingnews.comTandem Diabetes Care (NASDAQ:TNDM) Upgraded at Leerink PartnrsApril 27, 2024 | americanbankingnews.comTandem Diabetes Care (NASDAQ:TNDM) Rating Increased to Outperform at SVB LeerinkApril 26, 2024 | msn.comLeerink Partners Upgrades Tandem Diabetes Care (TNDM)April 26, 2024 | americanbankingnews.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Average Recommendation of "Hold" by AnalystsApril 25, 2024 | americanbankingnews.comTandem Diabetes Care (TNDM) to Release Earnings on ThursdayApril 24, 2024 | americanbankingnews.comTandem Diabetes Care (NASDAQ:TNDM) Price Target Raised to $40.00 at Stifel NicolausApril 23, 2024 | morningstar.comTandem Diabetes Care IncApril 14, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - TNDMApril 9, 2024 | businesswire.comTandem Diabetes Care to Announce First Quarter 2024 Financial Results on May 2, 2024April 9, 2024 | gurufocus.comWhat's Driving Tandem Diabetes Care Inc's Surprising 25% Stock Rally?April 9, 2024 | finance.yahoo.comBullish Tandem Diabetes Care Insiders Loaded Up On US$725.5k Of StockApril 7, 2024 | fool.com1 Beaten-Down Stock That Could Make You RicherApril 5, 2024 | finance.yahoo.comShould You Invest in Tandem Diabetes Care (TNDM)?March 26, 2024 | fool.comWhy Tandem Diabetes Care Stock Was Zooming Higher TodaySee More Headlines Receive TNDM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today5/03/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:TNDM CUSIPN/A CIK1438133 Webwww.tandemdiabetes.com Phone(858) 366-6900FaxN/AEmployees2,400Year Founded2006Price Target and Rating Average Stock Price Target$43.45 High Stock Price Target$62.00 Low Stock Price Target$33.00 Potential Upside/Downside-8.7%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($3.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-222,610,000.00 Net Margins-29.77% Pretax Margin-29.46% Return on Equity-31.48% Return on Assets-10.75% Debt Debt-to-Equity Ratio0.91 Current Ratio3.83 Quick Ratio3.02 Sales & Book Value Annual Sales$747.72 million Price / Sales3.86 Cash FlowN/A Price / Cash FlowN/A Book Value$4.81 per share Price / Book9.30Miscellaneous Outstanding Shares64,560,000Free Float63,143,000Market Cap$2.89 billion OptionableOptionable Beta1.10 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. John F. Sheridan (Age 69)President, CEO & Director Comp: $988.35kMs. Leigh A. Vosseller (Age 50)Executive VP, CFO & Treasurer Comp: $543.38kMs. Susan M. Morrison (Age 45)Executive VP & Chief Administrative Officer Comp: $538.21kMr. David B. Berger Esq. (Age 54)Transitional Advisor Comp: $543.38kMr. Brian B. Hansen (Age 56)Executive Officer Comp: $561.74kMs. Elizabeth Anne Gasser (Age 48)Executive Vice President and Chief Strategy & Product Officer Comp: $542.91kMr. Mark Novara (Age 49)Executive VP & Chief Commercial Officer Comp: $169.6kMr. Rick A. Carpenter (Age 61)Chief Technical Officer Ms. Shannon M. Hansen (Age 58)Executive VP, Chief Legal, Privacy & Compliance Officer and Secretary Mr. Tom FoxChief Human Resources OfficerMore ExecutivesKey CompetitorsICU MedicalNASDAQ:ICUIIntegra LifeSciencesNASDAQ:IARTInari MedicalNASDAQ:NARIPROCEPT BioRoboticsNASDAQ:PRCTAlphatecNASDAQ:ATECView All CompetitorsInsiders & InstitutionsRiverPark Advisors LLCBought 9,237 shares on 5/3/2024Ownership: 0.016%Jennison Associates LLCBought 1,265,534 shares on 5/2/2024Ownership: 3.959%Baillie Gifford & Co.Sold 2,946 shares on 5/1/2024Ownership: 0.402%Janney Montgomery Scott LLCBought 1,493 shares on 5/1/2024Ownership: 0.053%Capstone Investment Advisors LLCBought 5,288 shares on 5/1/2024Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions TNDM Stock Analysis - Frequently Asked Questions Should I buy or sell Tandem Diabetes Care stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 1 sell rating, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TNDM shares. View TNDM analyst ratings or view top-rated stocks. What is Tandem Diabetes Care's stock price target for 2024? 11 Wall Street analysts have issued 12 month price targets for Tandem Diabetes Care's stock. Their TNDM share price targets range from $33.00 to $62.00. On average, they predict the company's stock price to reach $43.45 in the next twelve months. This suggests that the stock has a possible downside of 2.8%. View analysts price targets for TNDM or view top-rated stocks among Wall Street analysts. How have TNDM shares performed in 2024? Tandem Diabetes Care's stock was trading at $29.58 on January 1st, 2024. Since then, TNDM shares have increased by 51.2% and is now trading at $44.72. View the best growth stocks for 2024 here. When is Tandem Diabetes Care's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our TNDM earnings forecast. How were Tandem Diabetes Care's earnings last quarter? Tandem Diabetes Care, Inc. (NASDAQ:TNDM) issued its quarterly earnings data on Wednesday, February, 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $0.04. The medical device company earned $196.80 million during the quarter, compared to the consensus estimate of $204.86 million. Tandem Diabetes Care had a negative net margin of 29.77% and a negative trailing twelve-month return on equity of 31.48%. What ETFs hold Tandem Diabetes Care's stock? ETFs with the largest weight of Tandem Diabetes Care (NASDAQ:TNDM) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Fidelity Digital Health ETF (FDHT), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Equipment ETF (XHE), Syntax Stratified SmallCap ETF (SSLY), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Invesco Nasdaq Future Gen 200 ETF (QQQS) and Fidelity Disruptive Medicine ETF (FMED). When did Tandem Diabetes Care's stock split? Shares of Tandem Diabetes Care reverse split on the morning of Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What guidance has Tandem Diabetes Care issued on next quarter's earnings? Tandem Diabetes Care updated its second quarter 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $205.0 million-$205.0 million, compared to the consensus revenue estimate of $205.0 million. What is John Sheridan's approval rating as Tandem Diabetes Care's CEO? 11 employees have rated Tandem Diabetes Care Chief Executive Officer John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among the company's employees. What other stocks do shareholders of Tandem Diabetes Care own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Block (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL). Who are Tandem Diabetes Care's major shareholders? Tandem Diabetes Care's stock is owned by a variety of retail and institutional investors. Top institutional investors include Jennison Associates LLC (3.96%), Principal Financial Group Inc. (0.55%), Baillie Gifford & Co. (0.40%), Assenagon Asset Management S.A. (0.35%), BNP Paribas Financial Markets (0.23%) and Mirae Asset Global Investments Co. Ltd. (0.22%). Insiders that own company stock include Brian B Hansen, Christopher J Twomey, Christopher J Twomey, David B Berger, Dick Allen, Elizabeth Anne Gasser, James Leal, John F Sheridan, Kathleen Mcgroddy-Goetz, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson, Rebecca B Robertson, Shannon Marie Hansen and Susan Morrison. View institutional ownership trends. How do I buy shares of Tandem Diabetes Care? Shares of TNDM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TNDM) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Gold Grab of the CenturyColonial MetalsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsREAD THIS – If You Missed Out On The AI BoomBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tandem Diabetes Care, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
